Fountain Healthcare Partners

Co-founders Dr. Manus Rogan and Aidan King serve as Managing Partners and lead investment decisions alongside Partners Ena Prosser and Justin Lynch. All four trace their life sciences venture experience to operating or venture roles at Elan Corporation. Rogan focuses on European investments and fund raising, while King concentrates on US deals. Prosser and Lynch each manage portfolio company relationships and sector-specific sourcing.

Fountain only makes direct investments in the companies it backs. The firm leads or co-leads syndicates, concentrating its capital on seed and early-stage life sciences companies. It does not operate as a fund-of-funds or allocate to external venture managers.

Fountain focuses exclusively on seed and early-stage life sciences companies. The firm's published investment criteria include an expectation for a significant exit within three to six years of the initial investment, a timeframe consistent with venture-stage biopharma and device assets that can reach clinical inflection points relatively quickly.

Fountain does not invest outside life sciences. The firm's website confirms a strict focus on specialty pharma, biopharmaceuticals, medical devices and diagnostics. Generalist technology, consumer, fintech, and infrastructure verticals are entirely absent from its mandate.

Fountain was co-founded by former Elan Corporation venture executives. Dr. Manus Rogan and Aidan King each spent roughly a decade at Elan, and Partner Ena Prosser held R&D and project management roles there. The firm's founding was not seeded by a single family's wealth but by the experience and track record its partners built inside Elan's corporate venture group.